Global Immunosuppressive Drug Market Research and Forecast 2022-2028

Description

List of Tables

Immunosuppressive Drug Market Share, Growth, Competitive Analysis By Application (Heart Transplant, Kidney Transplant, Liver Transplant, Lungs Transplant, and other), By Drug Class (, Calcineurin Inhibitor, Antiproliferative Agent, mTOR Inhibitors, Steroids and other), By Drug Type (Patented and Generic) Forecast Period 2021-2027

The global immunosuppressive drug Market is growing at a significant CAGR of 14.2% during the forecast period. The major factors that are augmenting the growth of the immunosuppressive drug market include the increasing transplant rate of the organ all across the globe. The Immunosuppressive drug is used at the end-stage of organ transplants such as after the transplant of the kidney, heart, and liver. The drug is provided so that it can reduce the risk of organs getting rejected by the immune system of the human body. The increasing demand for organ replacement as well as the growing adoption of tissue engineering in organ transplant is significantly contributing to market growth. Adopting new medication options such as scleroderma treatment and increasing usage of tissue engineering are the factors that brought new opportunities to the Immunosuppressive drug market. However, certain factors are restraining the growth of the market such as the high cost of the drug as well as a shortage of organ donors for transplant.

Segmental Outlook

The market is segmented on the basis of application, drug class, and drug type. By application, the market is segmented into heart transplant, kidney transplant, liver transplant, lungs transplant, and others. Further, based on the drug class segment, the market is segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Further, based on drug type, the market is segmented into patented and generic drugs.

Global Immunosuppressive Drug Market Share by Application, 2020 (%)

Global Immunosuppressive Drug Market Share by Application

On the basis of application, the market is segmented into heart transplant, kidney transplant, liver transplant, lungs transplant, and others. The cases for kidney failure is rising frequently that is resulting in kidney transplant. It is expected that kidney transplants will have a considerable share in the market growth. On the basis of drug type, the market is segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Calcineurin inhibitor is expected to have a major market share among all drug types as it is widely used in solid organ transplantation.

Regional Outlooks

The global immunosuppressive drug market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of geography, the market is divided into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to be among the leading region in the market. The market is growing due to rising chronic disease and transplant procedures. Chronic diseases are affecting the organs that will lead to replacing them. The US holds a major market share in the market during the forecast period.

Asia-Pacific will have considerable growth in the global Immunosuppressive Drug Market

Asia-Pacific is estimated to be the fastest-growing market during the forecast period. Several factors are driving the growth of the market such as rising consumption of alcohol that is resulting in damaged liver and kidney as well as a rising chronic disease that is affecting the organs. Moreover, rising government initiatives to reduce the prices of drugs are also motivating factors for the market.

Market Players Outlook

Key players of the immunosuppressive drug market are AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Cipla Ltd., Dr. Reddy's Laboratories Ltd., F Hoffmann-La Roche Ltd. among others. In order to survive in the market, these players adopt different marketing strategies such as mergers, acquisitions, product launches, and geographical expansion so on. For instance, in November 2020, Lupin Ltd. launched a generic immunosuppressant Tacrolimus capsule in the US after its partnership with Concord Biotech, it received approval for the product from the US healthcare regulator.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Immunosuppressive Drug Market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2018397

1. Report Summary

1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. By Application
- 5.1.1. Heart Transplant
- 5.1.2. Kidney Transplant
- 5.1.3. Liver Transplant
- 5.1.4. Lungs Transplant
- 5.1.5. Other (Bone Marrow Transplant)
5.2. By Drug Class
- 5.2.1. Calcineurin Inhibitor
- 5.2.2. Antiproliferative Agent
- 5.2.3. mTOR Inhibitors
- 5.2.4. Steroids
- 5.2.5. Other
5.3. By Drug Type
- 5.3.1. Patented
- 5.3.2. Generic

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles

7.1. Abbvie Inc.
7.2. Astellas Pharma Inc
7.3. Biocon Ltd.
7.4. Bristol-Myers Squibb Co.
7.5. Cadila Healthcare Ltd.
7.6. Dr. Reddy's Laboratories Ltd.
7.7. F. Hoffmann-La Roche Ltd.
7.8. Intas Pharmaceuticals Ltd (Accord Healthcare Ltd.)
7.9. LGM Pharma, LLC
7.10. Mylan NV
7.11. Novartis AG (Sandoz)
7.12. Pfizer Inc.
7.13. Sanofi SA
7.14. Taj Pharmaceuticals Ltd.
7.15. Topas Therapeutics GmbH
7.16. Teva Pharmaceutical Industries Ltd.
7.17. Veloxis Pharmaceuticals, Inc.